Published in Br J Clin Pharmacol on September 01, 1999
Pattern of sequence variation across 213 environmental response genes. Genome Res (2004) 3.93
Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin. Proc Natl Acad Sci U S A (2005) 2.39
Evaluation of cytochrome P450 2C9 activity in normal, healthy, adult Western Indian population by both phenotyping and genotyping. Indian J Pharmacol (2016) 1.40
Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population. Br J Clin Pharmacol (2002) 1.30
Frequency of cytochrome P450 2C9 mutant alleles in a Korean population. Br J Clin Pharmacol (2001) 1.26
Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population. Eur J Clin Pharmacol (2003) 1.20
Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population. Br J Clin Pharmacol (2001) 1.17
Cytochrome P450 2C9-CYP2C9. Pharmacogenet Genomics (2010) 1.16
Applications of CYP450 testing in the clinical setting. Mol Diagn Ther (2013) 1.08
Validation of a new fluorogenic real-time PCR assay for detection of CYP2C9 allelic variants and CYP2C9 allelic distribution in a German population. Br J Clin Pharmacol (2002) 1.05
Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing. Clin Pharmacol Ther (2014) 1.03
Influence of CYP2C9 and CYP2C19 genetic polymorphisms on phenytoin-induced neurological toxicity in Indian epileptic patients. Eur J Clin Pharmacol (2010) 0.95
Genetic polymorphism of CYP2C9 and CYP2C19 in a Bolivian population: an investigative and comparative study. Eur J Clin Pharmacol (2005) 0.95
CYP2C9*1B promoter polymorphisms, in linkage with CYP2C19*2, affect phenytoin autoinduction of clearance and maintenance dose. J Pharmacol Exp Ther (2009) 0.91
Pharmacokinetics and clinical effects of phenytoin and fosphenytoin in children with severe malaria and status epilepticus. Br J Clin Pharmacol (2003) 0.89
CYP2C9 genotypes and diclofenac metabolism in Spanish healthy volunteers. Eur J Clin Pharmacol (2003) 0.86
CYP2C9 polymorphism and warfarin dose requirements. Br J Clin Pharmacol (2002) 0.85
Genotype-phenotype analysis of CYP2C19 in healthy saudi individuals and its potential clinical implication in drug therapy. Int J Med Sci (2013) 0.84
Therapeutic dosing of acenocoumarol: proposal of a population specific pharmacogenetic dosing algorithm and its validation in north Indians. PLoS One (2012) 0.84
Pharmacogenomic association study on the role of drug metabolizing, drug transporters and drug target gene polymorphisms in drug-resistant epilepsy in a north Indian population. Indian J Hum Genet (2011) 0.84
Phenytoin pharmacokinetics and clinical effects in African children following fosphenytoin and chloramphenicol coadministration. Br J Clin Pharmacol (2002) 0.83
Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans. Br J Clin Pharmacol (2003) 0.82
CYP2C9 genetic variants and losartan oxidation in a Turkish population. Eur J Clin Pharmacol (2004) 0.81
From evidence based medicine to mechanism based medicine. Reviewing the role of pharmacogenetics. Int J Clin Pharm (2010) 0.80
The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements in an adult Turkish population. Heart Vessels (2010) 0.80
VKORC1 and CYP2C9 polymorphisms are associated with warfarin dose requirements in Turkish patients. Eur J Clin Pharmacol (2008) 0.80
Genotyping of CYP2C9 and VKORC1 in the Arabic population of Al-Ahsa, Saudi Arabia. Biomed Res Int (2013) 0.79
Biomarkers for antiepileptic drug response. Biomark Med (2011) 0.79
Possible role of CYP2C9 & CYP2C19 single nucleotide polymorphisms in drug refractory epilepsy. Indian J Med Res (2011) 0.78
Cytochrome P450 2C9 (CYP2C9) polymorphisms in Chinese Li population. Int J Clin Exp Med (2015) 0.78
The effect of polymorphic metabolism enzymes on serum phenytoin level. Neurol Sci (2014) 0.77
Analysis of CYP2C9*2, CYP2C9*3 and VKORC1 -1639 G>A polymorphisms in a population from South-Eastern Europe. J Cell Mol Med (2012) 0.77
Polymorphisms of cytochrome p450 genes in three ethnic groups from Russia. Balkan Med J (2012) 0.77
An acenocoumarol dose algorithm based on a South-Eastern European population. Eur J Clin Pharmacol (2013) 0.76
Pharmacogenomics of Drug Metabolizing Enzymes and Transporters: Relevance to Precision Medicine. Genomics Proteomics Bioinformatics (2016) 0.76
Drug-induced gingival overgrowth: the genetic dimension. N Am J Med Sci (2014) 0.75
CYP2C9 variants as a risk modifier of NSAID-related gastrointestinal bleeding: a case-control study. Pharmacogenet Genomics (2016) 0.75
Lipid-lowering effect of fluvastatin in relation to cytochrome P450 2C9 variant alleles frequently distributed in the Czech population. Med Sci Monit (2012) 0.75
Update on the Genetic Polymorphisms of Drug-Metabolizing Enzymes in Antiepileptic Drug Therapy. Pharmaceuticals (Basel) (2010) 0.75
CYP2C9, CYP2C19, ABCB1 genetic polymorphisms and phenytoin plasma concentrations in Mexican-Mestizo patients with epilepsy. Pharmacogenomics J (2015) 0.75
A prospective study to assess the association between genotype, phenotype and Prakriti in individuals on phenytoin monotherapy. J Ayurveda Integr Med (2017) 0.75
Cytochrome P450 (CYP2C9*2,*3) & vitamin-K epoxide reductase complex (VKORC1 -1639G<A) gene polymorphisms & their effect on acenocoumarol dose in patients with mechanical heart valve replacement. Indian J Med Res (2013) 0.75
Frequencies of CYP2C9 polymorphisms in North Indian population and their association with drug levels in children on phenytoin monotherapy. BMC Pediatr (2016) 0.75
The allele frequency of CYP2C9 and VKORC1 in the Southern Khorasan population. Res Pharm Sci (2017) 0.75
Generalized Multifactor Dimensionality Reduction (GMDR) Analysis of Drug-Metabolizing Enzyme-Encoding Gene Polymorphisms may Predict Treatment Outcomes in Indian Breast Cancer Patients. World J Surg (2016) 0.75
Impact of Genetic Polymorphisms on Phenytoin Pharmacokinetics and Clinical Outcomes in the Middle East and North Africa Region. Drugs R D (2017) 0.75
In vitro metabolism of exemestane by hepatic cytochrome P450s: impact of nonsynonymous polymorphisms on formation of the active metabolite 17β-dihydroexemestane. Pharmacol Res Perspect (2017) 0.75
Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol (1998) 3.17
Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics (1994) 2.55
Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics (1994) 2.32
Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms. Arch Biochem Biophys (1996) 1.56
Genetic association between sensitivity to warfarin and expression of CYP2C9*3. Pharmacogenetics (1997) 1.47
Site-directed mutation studies of human liver cytochrome P-450 isoenzymes in the CYP2C subfamily. Biochem J (1993) 1.41
Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes. Clin Pharmacol Ther (1998) 1.34
Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy. Pharmacogenetics (1995) 1.31
Validation of the tolbutamide metabolic ratio for population screening with use of sulfaphenazole to produce model phenotypic poor metabolizers. Clin Pharmacol Ther (1990) 1.26
Interethnic variation of drug metabolism. Trends Pharmacol Sci (1991) 1.25
Allelic and functional variability of cytochrome P4502C9. Pharmacogenetics (1997) 1.16
Lung cancer risk in relation to the CYP2C9*1/CYP2C9*2 genetic polymorphism among African-Americans and Caucasians in Los Angeles County, California. Pharmacogenetics (1996) 1.08
Application of the phenotyped panel approach to the detection of polymorphism of drug oxidation in man [proceedings]. Br J Pharmacol (1979) 1.08
Stereochemistry of aromatic phenytoin hydroxylation in various drug hydroxylation phenotypes in humans. J Pharmacol Exp Ther (1987) 1.03
Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4'-hydroxylation activities in livers of Japanese and Caucasian populations. Pharmacogenetics (1997) 1.01
Extent of urinary excretion of p-hydroxyphenytoin in healthy subjects given phenytoin. Ther Drug Monit (1985) 0.97
Metabolism of Meloxicam in human liver involves cytochromes P4502C9 and 3A4. Xenobiotica (1998) 0.96
Phenotyping of CYP2C19 with enantiospecific HPLC-quantification of R- and S-mephenytoin and comparison with the intron4/exon5 G-->A-splice site mutation. Pharmacogenetics (1995) 0.96
Roles of two allelic variants (Arg144Cys and Ile359Leu) of cytochrome P4502C9 in the oxidation of tolbutamide and warfarin by human liver microsomes. Xenobiotica (1998) 0.92
Identification of cytochromes P450 involved in the human liver microsomal metabolism of the thromboxane A2 inhibitor seratrodast (ABT-001). Drug Metab Dispos (1997) 0.83
Effect of 5-(p-hydroxyphenyl)-5-phenylhydantoin (p-HPPH) enantiomers, major metabolites of phenytoin, on the occurrence of chronic-gingival hyperplasia: in vivo and in vitro study. Eur J Clin Pharmacol (1995) 0.82
Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A (2000) 5.89
Recognition of stress-induced MHC molecules by intestinal epithelial gammadelta T cells. Science (1998) 5.05
Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. Proc Natl Acad Sci U S A (1996) 4.69
An activating immunoreceptor complex formed by NKG2D and DAP10. Science (1999) 4.56
Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc Natl Acad Sci U S A (1999) 4.40
Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet (1997) 3.08
Protein kinase C phosphorylates the inhibitory guanine-nucleotide-binding regulatory component and apparently suppresses its function in hormonal inhibition of adenylate cyclase. Eur J Biochem (1985) 3.04
Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry (2004) 2.98
Primary gastric B-cell lymphoma: results of a prospective multicenter study. The German-Austrian Gastrointestinal Lymphoma Study Group. Gastroenterology (2000) 2.65
Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther (2001) 2.62
Functional significance of a C-->A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol (1999) 2.57
The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics (2001) 2.21
The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin. Clin Pharmacol Ther (2009) 2.19
The risks of blood transfusion: the relative influence of acquired immunodeficiency syndrome and non-A, non-B hepatitis. Am J Med (1992) 2.12
Higher blood flow and circulating NO products offset high-altitude hypoxia among Tibetans. Proc Natl Acad Sci U S A (2007) 2.07
Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum). Clin Pharmacol Ther (1999) 1.96
Autoradiographic study of mannan incorporation into the growing cell walls of Saccharomyces cerevisiae. J Bacteriol (1974) 1.94
Nomenclature for human CYP2D6 alleles. Pharmacogenetics (1996) 1.91
A new rapid slide test for infectious mononucleosis. JAMA (1965) 1.82
Intravenous levetiracetam in the treatment of benzodiazepine refractory status epilepticus. J Neurol Neurosurg Psychiatry (2007) 1.80
Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am J Hum Genet (1995) 1.79
A C4887A polymorphism in exon 7 of human CYP1A1: population frequency, mutation linkages, and impact on lung cancer susceptibility. Cancer Res (1996) 1.74
The surrogate light chain in B-cell development. Immunol Today (1993) 1.64
Dense growth of aerobic bacteria in a bench-scale fermentor. Biotechnol Bioeng (1976) 1.62
Anti-CD16/CD30 bispecific antibody treatment for Hodgkin's disease: role of infusion schedule and costimulation with cytokines. Clin Cancer Res (2001) 1.62
Reduced nicotinamide adenine dinucleotide phosphate (NADPH)-dependent formation and breakdown of hydrogen peroxide during mixed function oxidation reactions in liver microsomes. Arch Biochem Biophys (1975) 1.60
Prevalence of the metabolic syndrome among Turkish adults. Eur J Clin Nutr (2006) 1.59
CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand (2001) 1.59
Analysis of the SlyA-controlled expression, subcellular localization and pore-forming activity of a 34 kDa haemolysin (ClyA) from Escherichia coli K-12. Mol Microbiol (1999) 1.55
Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics J (2006) 1.53
Characterization of the glutathione S-transferase GSTT1 deletion: discrimination of all genotypes by polymerase chain reaction indicates a trimodular genotype-phenotype correlation. Pharmacogenetics (2000) 1.52
Critical evaluation of the effect of valerian extract on sleep structure and sleep quality. Pharmacopsychiatry (2000) 1.52
Endoscopic evaluation of exercise-induced pulmonary hemorrhage and chronic obstructive pulmonary disease in association with poor performance in racing Standardbreds. J Am Vet Med Assoc (1990) 1.51
Role of Kozak sequence polymorphism of platelet glycoprotein Ibalpha as a risk factor for coronary artery disease and catheter interventions. J Am Coll Cardiol (2001) 1.51
Secretion of cell-wall glycoproteins by yeast protoplasts. Effect of 2-deoxy-D-glucose and cycloheximide. Biochem J (1970) 1.48
Lack of DNA synthesis among CD34+ cells in cord blood and in cytokine-mobilized blood. Br J Haematol (1996) 1.48
SlyA, a regulatory protein from Salmonella typhimurium, induces a haemolytic and pore-forming protein in Escherichia coli. Mol Gen Genet (1995) 1.45
Reduced procedural risk for coronary catheter interventions in carriers of the coagulation factor VII-Gln353 gene. J Am Coll Cardiol (2000) 1.45
Arterial hypoxemia following the administration of sublingual nitroglycerin. Am Heart J (1978) 1.44
Effect of surgical repair on the neurologic function in infants with lipomeningocele. Pediatr Neurosurg (1993) 1.40
Modulation of adenylate cyclase of human platelets by phorbol ester. Impairment of the hormone-sensitive inhibitory pathway. Eur J Biochem (1985) 1.39
Immunosuppressive properties of cyclosporin metabolites. Lancet (1989) 1.39
Hydrogen peroxide in hepatic microsomes. Methods Enzymol (1978) 1.38
Demonstration of cGMP-dependent protein kinase and cGMP-dependent phosphorylation in cell-free extracts of platelets. Eur J Biochem (1986) 1.31
Extracellular beta-glucanases of the yeast, Saccharomyces cerevisiae. Biochim Biophys Acta (1973) 1.31
Genotype and phenotype of glutathione S-transferase class mu isoenzymes mu and psi in lung cancer patients and controls. Cancer Res (1993) 1.29
Protection of rhesus monkeys from fatal Lassa fever by vaccination with a recombinant vaccinia virus containing the Lassa virus glycoprotein gene. Proc Natl Acad Sci U S A (1989) 1.25
Metabolism of 2-deoxy-D glucose by Baker's yeast. IV. Incorporation of 2-deoxy-D-glucose into cell wall mannan. Biochim Biophys Acta (1972) 1.24
Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population. Clin Pharmacol Ther (1999) 1.23
Increase of cytochrome P450IA2 activity by omeprazole: evidence by the 13C-[N-3-methyl]-caffeine breath test in poor and extensive metabolizers of S-mephenytoin. Clin Pharmacol Ther (1992) 1.22
High mobility, low voltage operating C(60) based n-type organic field effect transistors. Synth Met (2011) 1.21
Xylan-degrading activity in yeasts: growth on xylose, xylan and hemicelluloses. Folia Microbiol (Praha) (1978) 1.20
Association of cyclophosphamide pharmacokinetics to polymorphic cytochrome P450 2C19. Pharmacogenomics J (2005) 1.19
Crystal structure of the MHC class I homolog MIC-A, a gammadelta T cell ligand. Immunity (1999) 1.19
A1/A2 polymorphism of glycoprotein IIIa and association with excess procedural risk for coronary catheter interventions: a case-controlled study. Lancet (1999) 1.18
Mechanism of 2-deoxy-D-glucose inhibition of cell-wall polysaccharide and glycoprotein biosyntheses in Saccharomyces cerevisiae. Eur J Biochem (1975) 1.18
Commissioning of a micro multi-leaf collimator and planning system for stereotactic radiosurgery. Radiother Oncol (1999) 1.18
T cells from patients with Hodgkin's disease have a defective T-cell receptor zeta chain expression that is reversible by T-cell stimulation with CD3 and CD28. Blood (1996) 1.17
Effect of 2-deoxyglucose on cell wall formation in Saccharomyces cerevisiae and its relation to cell growth inhibition. J Bacteriol (1971) 1.13
Maximal exponential growth rate and yield of E. coli obtainable in a bench-scale fermentor. Biotechnol Bioeng (1974) 1.13
A single origin of phenylketonuria in Yemenite Jews. Nature (1990) 1.11
The oxidation of fatty acids by a particulate fraction from desert-locust (Schistocerca gregaria) thorax tissues. Biochem J (1960) 1.10
In vivo CTL induction with point-substituted ovalbumin peptides: immunogenicity correlates with peptide-induced MHC class I stability. Vaccine (1995) 1.10
High CA repeat numbers in intron 13 of the endothelial nitric oxide synthase gene and increased risk of coronary artery disease. Pharmacogenetics (2000) 1.09
Arylamine N-acetyltransferase activity in man. Drug Metab Rev (1999) 1.09
Expansion of cytokine-producing CD4-CD8- T cells associated with abnormal Fas expression and hypereosinophilia. J Exp Med (1996) 1.08
[The value of pharmacogenetic tests in antidepressive medication therapy]. Nervenarzt (2005) 1.07
Progressive liver calcifications in neonatal coxsackievirus infection. Pediatr Radiol (2000) 1.07
Accelerated caffeine metabolism after omeprazole treatment is indicated by urinary metabolite ratios: coincidence with plasma clearance and breath test. Clin Pharmacol Ther (1994) 1.06
Crystal structure of the murine NK cell-activating receptor NKG2D at 1.95 A. Nat Immunol (2001) 1.06
RP1, a new member of the adenomatous polyposis coli-binding EB1-like gene family, is differentially expressed in activated T cells. J Immunol (1997) 1.06
Evaluation of in vivo parameters of drug metabolizing enzyme activity in man after administration of clemastine, phenobarbital or placebo. Eur J Clin Pharmacol (1975) 1.06
The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels. Pharmacogenomics J (2001) 1.05